Findings

What do systematic reviews say?

4,721 questions · 19,640 findings · 2,039 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 3,754 · 19.1%GRADE not reported 1,273 · 6.5%Very low 4,859 · 24.7%Low 5,568 · 28.4%Moderate 3,240 · 16.5%High 946 · 4.8%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Pregabalin vs active comparators

Adverse effect: fatigue · people with drug‐resistant focal epilepsy

1 finding from 1 review

Pregabalin add‐on for drug‐resistant focal epilepsy 2022 · Cochrane Headline outcomes only
1.72 [0.77, 3.83]
1 study · 293 participants
Low

Pregabalin vs active comparators

Adverse effects: headache · people with drug‐resistant focal epilepsy

1 finding from 1 review

Pregabalin add‐on for drug‐resistant focal epilepsy 2022 · Cochrane Headline outcomes only
0.83 [0.41, 1.65]
3 studies · 1286 participants
Very low

Pregabalin vs active comparators

Nausea · people with drug‐resistant focal epilepsy

1 finding from 1 review

Pregabalin add‐on for drug‐resistant focal epilepsy 2022 · Cochrane Headline outcomes only
0.2 [0.04, 1.01]
1 study · 509 participants
Very low

Pregabalin vs active comparators

Somnolence · people with drug‐resistant focal epilepsy

1 finding from 1 review

Pregabalin add‐on for drug‐resistant focal epilepsy 2022 · Cochrane Headline outcomes only
1.16 [0.88, 1.53]
3 studies · 1286 participants
Low

Pregabalin vs active comparators

Weight gain · people with drug‐resistant focal epilepsy

1 finding from 1 review

Pregabalin add‐on for drug‐resistant focal epilepsy 2022 · Cochrane Headline outcomes only
2.87 [0.94, 8.75]
3 studies · 1286 participants
Low

Pregabalin vs placebo

Seizure freedom · people with drug‐resistant focal epilepsy

1 finding from 1 review

Pregabalin add‐on for drug‐resistant focal epilepsy 2022 · Cochrane Headline outcomes only
3.94 [1.5, 10.37]
4 studies · 1125 participants
Moderate

Pregabalin vs placebo

Treatment withdrawal · people with drug‐resistant focal epilepsy

Pregabalin probably leads to higher treatment withdrawal for any reason compared with placebo (moderate certainty).

1 finding from 1 review

Pregabalin add‐on for drug‐resistant focal epilepsy 2022 · Cochrane Headline outcomes only
RR 1.33 [1.1, 1.6]
9 studies · 2663 participants
Moderate

Pregabalin vs placebo

Withdrawals due to adverse events · people with drug‐resistant focal epilepsy

Pregabalin probably leads to higher treatment withdrawal due to adverse effects compared with placebo (moderate certainty).

1 finding from 1 review

Pregabalin add‐on for drug‐resistant focal epilepsy 2022 · Cochrane Headline outcomes only
RR 2.6 [1.86, 3.64]
9 studies · 2663 participants
Moderate

Pregabalin vs placebo

Ataxia · people with drug‐resistant focal epilepsy

Pregabalin may leads to higher adverse effect: ataxia compared with placebo (low certainty).

1 finding from 1 review

Pregabalin add‐on for drug‐resistant focal epilepsy 2022 · Cochrane Headline outcomes only
RR 3.9 [2.05, 7.42]
6 studies · 1868 participants
Low

Pregabalin vs placebo

Dizziness · people with drug‐resistant focal epilepsy

Pregabalin may leads to higher adverse effect: dizziness compared with placebo (low certainty).

1 finding from 1 review

Pregabalin add‐on for drug‐resistant focal epilepsy 2022 · Cochrane Headline outcomes only
RR 3.15 [2.23, 4.44]
7 studies · 2193 participants
Low

Pregabalin vs placebo

Adverse effect: fatigue · people with drug‐resistant focal epilepsy

Pregabalin showed no clear difference in adverse effect: fatigue compared with placebo (low certainty).

1 finding from 1 review

Pregabalin add‐on for drug‐resistant focal epilepsy 2022 · Cochrane Headline outcomes only
RR 1.35 [0.94, 1.93]
8 studies · 2448 participants
Low

Prednisone plus azathioprine vs prednisone

Disease control · bullous pemphigoid

It is very uncertain whether prednisone plus azathioprine changes disease control (at 6 months) compared with prednisone (very low certainty).

1 finding from 1 review

Interventions for bullous pemphigoid 2023 · Cochrane Headline outcomes only
RR 0.93 [0.52, 1.66]
1 study · 67 participants
Very low

Prednisone plus azathioprine vs prednisone

Mortality (at 6 months) · bullous pemphigoid

It is very uncertain whether prednisone plus azathioprine changes mortality (at 6 months) compared with prednisone (very low certainty).

1 finding from 1 review

Interventions for bullous pemphigoid 2023 · Cochrane Headline outcomes only
RR 1.03 [0.35, 3.06]
1 study · 67 participants
Very low

Prednisone plus azathioprine vs prednisone

Quality of life ‐ not measured · bullous pemphigoid

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for bullous pemphigoid 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Prednisone plus azathioprine vs prednisone

Adverse events · bullous pemphigoid

1 finding from 1 review

Interventions for bullous pemphigoid 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Very low

Feedback on prescribing errors vs education on prescribing errors

Medication errors ( · adults

It is very uncertain whether feedback on prescribing errors changes medication errors ( compared with education on prescribing errors (very low certainty).

1 finding from 1 review

Reducing medication errors for adults in hospital settings 2021 · Cochrane Headline outcomes only
OR 0.59 [0.2, 1.76]
2 studies · 2 participants
Very low

Antidepressants vs placebo

Treatment success (caries lesion arrest or restoration survival) · children (4 to 18 years) with functional abdominal pain disorders

Antidepressant showed no clear difference in treatment success compared with placebo (low certainty).

1 finding from 1 review

Antidepressants for functional abdominal pain disorders in children and adolescents 2021 · Cochrane Headline outcomes only
RR 1.17 [0.87, 1.56]
2 studies · 205 participants
Low

Antidepressants vs placebo

Withdrawals due to adverse events · children (4 to 18 years) with functional abdominal pain disorders

Antidepressant showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).

1 finding from 1 review

Antidepressants for functional abdominal pain disorders in children and adolescents 2021 · Cochrane Headline outcomes only
RR 3.17 [0.65, 15.33]
3 studies · 238 participants
Low

Methylprednisolone plus azathioprine vs methylprednisolone plus dapsone

Disease control (time when steroid could be discontinued) · bullous pemphigoid

1 finding from 1 review

Interventions for bullous pemphigoid 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 54 participants
Very low

Methylprednisolone plus azathioprine vs methylprednisolone plus dapsone

Mortality at 1 year · bullous pemphigoid

It is very uncertain whether methylprednisolone plus azathioprine changes mortality at 1 year compared with methylprednisolone plus dapsone (very low certainty).

1 finding from 1 review

Interventions for bullous pemphigoid 2023 · Cochrane Headline outcomes only
RR 0.33 [0.04, 3.01]
1 study · 54 participants
Very low